<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00034684</url>
  </required_header>
  <id_info>
    <org_study_id>P00701</org_study_id>
    <nct_id>NCT00034684</nct_id>
  </id_info>
  <brief_title>Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)</brief_title>
  <official_title>Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of an oral Farnesyl
      Protein Transferase Inhibitor (SCH 66336) as a single agent in patients with Advanced
      Myelodysplastic Syndrome, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia in Blast
      Crisis, or Acute Lymphoblastic Leukemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2001</start_date>
  <completion_date type="Actual">October 2003</completion_date>
  <primary_completion_date type="Actual">October 2003</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">132</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Leukemia, Myeloid, Chronic</condition>
  <condition>Blast Crisis</condition>
  <condition>Leukemia, Lymphocytic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Farnesyl Protein Transferase Inhibitor</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically documented chronic myelogenous leukemia in blast crisis,
             myelodysplasia, acute myelogenous leukemia, or acute lymphocytic leukemia.

          -  Life expectancy of 12 weeks or greater.

          -  ECOG Performance Status less than or equal to 2.

          -  Meets protocol requirements for specified laboratory values.

          -  No manifestations of a malabsorption syndrome.

        Exclusion Criteria:

          -  Patients who have received more than three chemotherapy regimens for more than three
             recurrences of the disease.

          -  Poor medical risks because of nonmalignant systemic disease as well as those with
             active uncontrolled conditions.

          -  Patients who have received investigational therapy of any type within 30 days prior to
             administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Italy</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2002</study_first_submitted>
  <study_first_submitted_qc>May 1, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2002</study_first_posted>
  <last_update_submitted>June 16, 2015</last_update_submitted>
  <last_update_submitted_qc>June 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Myelodysplastic Syndromes</keyword>
  <keyword>Leukemia, Myeloid</keyword>
  <keyword>Leukemia, Lymphocytic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

